Skip to main content
. 2020 Sep 1;8(6):827–837. doi: 10.1016/j.gendis.2020.08.010

Figure 3.

Figure 3

Relationships between the expression of CBX4 and clinicopathological parameters in GC patients. (A) CBX4 expression was significantly associated with tumor grade, and as tumor grade increased, the expression of CBX4 tended to increase. The highest expression of CBX4 was discovered in grade 2 tumors. ∗P < 0.05, ∗∗∗P < 0.001. (B) CBX4 expression was remarkably related to individual cancer stage in GC patients, and patients with cancer at a more advanced stage tended to express higher levels of CBX4. The highest CBX4 expression was found in patients with stage 3 cancer. ∗∗∗P < 0.001. (C) There was no association between the expression of CBX4 and patient's gender. (D) Higher CBX4 expression was significantly correlated with a shorter overall survival (OS) in GC patients.